Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pending regulations promote pre-emption

This article was originally published in The Tan Sheet

Executive Summary

FDA inserts pre-emption language into seven finalized proposed rules, the American Association for Justice reports in a list of the pending rules. In a report critical of the Bush administration's inclusion of such language in agency-wide regulations, AAJ says pre-emption provides a "get out of jail free" card to companies. FDA first mandated pre-emption in the 2006 physician labeling rule. Similar language is in proposed rules on pregnancy and lactation labeling, skin bleaching drug products, OTC drug labeling, OTC analgesics, labeling on calcium claims, sunscreen labels and a proposed fatty acid rule (1"The Tan Sheet" June 9, 2008, In Brief). FDA proposed three of the rules in 2006 and three in 2007. They go into effect 60 days before President Bush leaves office

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel